Health enSuite Caregivers is an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote well-being and provides tools to help caregivers implement these strategies in their everyday lives. Health enSuite Caregivers is available online and as a smartphone app. Its development was informed by reviews of caregivers' needs and existing commercially available apps. A systematic search of commercially available smartphone applications for caregivers found that many apps did not consider each caregiver's unique needs, and were limited to psychoeducational content (no tools for self-management). Furthermore, most existing programs have not been rigorously tested or lack evidence to support their effectiveness.

开始日期2025-07-01

申办/合作机构

IWK Health Centre

NCT06910410

/ Not yet recruitingN/AIIT

An App to Disrupt the Link Between Social Media and Negative Body Image And Disordered Eating: A Pilot Study Of Feasibility, Acceptability, and Preliminary Efficacy

Social media (SM) is a key communication tool, particularly for young women aged 15-29. While SM fosters social connections, it is also linked to negative effects on mental health, including poor body image, low self-esteem, and maladaptive perfectionism. These issues arise due to social comparison with idealized images, especially on platforms like Instagram, which can contribute to disordered eating behaviours. Research suggests that reducing SM use can improve mental well-being, body image, and eating disorder symptoms. However, current interventions have not simultaneously addressed both reducing SM exposure and strengthening protective psychological factors. To address this gap, the proposed study aims to pilot BodyScreen, an intervention app designed to limit SM exposure while enhancing self-esteem and reducing perfectionism in young women at high risk for eating disorders. The study hypothesizes that BodyScreen will be feasible, acceptable, and effective in improving body image, self-esteem, and SM use, with sustained benefits at a 3-month follow-up. The intervention includes a virtual face-to-face session, mid-intervention email support, and a four-week app-based program using Ecological Momentary Interventions (EMIs). Participants will receive reminders to complete exercises designed to improve self-perception and reduce the negative effects of SM. Additionally, Ecological Momentary Assessment (EMA) will track real-time self-esteem, perfectionism, and body image, while mobile sensing will monitor SM use to tailor interactive exercises accordingly. By integrating exposure reduction with psychological strengthening, BodyScreen aims to provide a novel, evidence-based approach to mitigating the harmful effects of SM on young women's mental health.

开始日期2025-07-01

申办/合作机构

Dalhousie University

[+1]

NCT06797076

/ Not yet recruitingN/AIIT

Evaluating an App-Based Treatment for Chronic Headaches: The Health enSuite Migraine Study

Health enSuite is a suite of applications designed by our research team at the Centre of Research in Family Health at IWK Health. These applications evaluate virtual solutions for clinical problems and assist family doctors with their adult patients. Health enSuite will be utilized by Canadian family physicians targeting insomnia, anxiety, migraine headaches, and caregiver distress.Health enSuite Headache has been designed to make cognitive and behavioral techniques for managing migraine headaches readily available to primary care patients. The online program combines treatment elements that are effective in preventing and managing migraine headache pain, including trigger management, stress management, relaxation techniques, cognitive reappraisal, and psychoeducation (17, 18, 19, 20).

开始日期2025-06-02

申办/合作机构

IWK Health Centre

100 项与 IWK Health Centre 相关的临床结果

登录后查看更多信息

0 项与 IWK Health Centre 相关的专利（医药）

登录后查看更多信息

1,248

项与 IWK Health Centre 相关的文献（医药）

2025-05-01·Current Opinion in Clinical Nutrition & Metabolic Care

Improving the quality of donor human milk to take advantage of more of the health benefits of mother's own milk composition

Review

作者: Beggs, Megan R. ; Unger, Sharon ; O’Connor, Deborah L.

Purpose of reviewPasteurized donor human milk (PDHM) is the recommended supplement when there is inadequate volume of mother's own milk (MOM) for very low birth weight (<1500 g, VLBW) infants. Differences in the composition of these milks may impact growth, morbidities or long-term development of infants. The aim of this review is to highlight current trends in understanding compositional differences between MOM and PDHM, technological advances in processing PDHM, and infant outcomes when VLBW infants are fed these milks.Recent findingsReported differences in the composition between MOM and PDHM are due to several factors including when and how milk is collected, sampled for analysis, and processed. Systematic reviews and primary research studies demonstrate that PDHM reduces the risk of necrotizing enterocolitis in VLBW infants but is also associated with slower postnatal growth. Work is ongoing to determine if alternative approaches to processing PDHM can improve milk composition and thereby infant growth and neurodevelopment and reduce morbidity.SummaryPDHM is a key component of feeding VLBW infants when there is inadequate volume of MOM. Recent developments aim to optimize this source of nutrition and bioactive compounds for VLBW infants while further understanding limitations of its use.

2025-05-01·Journal of Medical Genetics

Canadian consensus for the assessment and testing of Lynch syndrome

Article

作者: Etchegary, Holly ; MacMillan, Andree ; Aronson, Melyssa ; Horte, Janice ; Rutka, Mari ; Hawrysh, Andrea ; Tiano, Teresa ; Waldman, Larissa ; Racher, Hilary ; Chamberlain, Erin ; Rusnak, Alison ; Kwon, Janice ; Jacob, Karine ; Palma, Laura ; Dawson, Lesa ; Rothenmund, Heidi ; Nuk, Jennifer ; Pollett, Aaron ; Dornan, Kimberly ; Holter, Spring ; Pautler, Stephen E ; Jessen, Jaime ; Sheffield, Brandon S ; Gallinger, Steven ; Ward, Thomas ; Kim, Raymond ; O'Loughlin, Melanie ; Bedard, Angela ; Kim, Christina A ; Singh, Harminder ; Semotiuk, Kara ; Kaurah, Pardeep ; Lerner-Ellis, Jordan ; Hyde, Angela ; Ferguson, Sarah ; Tabori, Uri

BackgroundLynch syndrome (LS) is an autosomal dominant cancer predisposition syndrome caused by a germline pathogenic variant, or epigenetic silencing, of a mismatch repair (MMR) gene, leading to a wide cancer spectrum with gene-specific penetrance. Ascertainment, assessment and testing of LS individuals is complex. A Canadian national guideline is needed to ensure equitable access to patient care across the country.MethodsThe Canadian Lynch Syndrome (CDN-LS) working group was formed in 2021, consisting of 37 multidisciplinary LS experts and patient partners. To formulate consensus statements, a national environmental scan, Canadian clinical survey and literature review were undertaken. The e-Delphi method was used to reach consensus statements among the CDN-LS group.ResultsThe CDN-LS group voted on 21 statements, and 18 statements were adopted with over 80% agreement, including 16 statements that had over 90% agreement. These statements provide comprehensive guidelines on universal MMR reflex testing, cascade tumour testing (MLH1promoter methylation,BRAF, somatic MMR), germline testing, therapeutics and patient advocacy.ConclusionThis is the first comprehensive Canadian guideline for LS providing guidance to genetic specialists, laboratories, primary care providers and healthcare providers caring for patients with LS. It is endorsed by the Canadian College of Medical Genetics and the Canadian Association of Genetic Counsellors. The consensus statements are presented as a model for standard of care that improves equitable access to health services for LS across the country. Future work should include a national consensus on LS surveillance, with a goal to harmonise LS care across all provincial and territorial healthcare authorities.

2025-05-01·The Journal of Pharmacology and Experimental Therapeutics

Acquired resistance to jadomycin B in human triple-negative breast cancer cells is associated with increased cyclooxygenase-2 expression

Article

作者: Goralski, Kerry B ; Groves, Brandon ; Jakeman, David L ; McKeown, Brendan T

Jadomycin B, produced by the soil bacterium Streptomyces venezuelae ISP5230, induces cytotoxicity in human breast cancer cells in vitro and has antitumoral effects in animal models. In models of multidrug-resistant, triple-negative breast cancer, jadomycin B has shown promise as it is not a substrate of ABCB1 and ABCG2 drug efflux transporters. The generation of reactive oxygen species and inhibition of topoisomerases are potential mechanisms of jadomycin B-mediated DNA damage and apoptosis. However, the mechanisms of jadomycin B's anticancer activity have not been fully elucidated. By gradually exposing MDA-MB-231 triple-negative human breast cancer cells to jadomycin B, we hypothesized that resistance could be selected to further understand jadomycin B's pharmacological mechanisms. A 3-fold increase in the jadomycin B IC₅₀ was observed in MDA-MB-231 cells exposed to increasing jadomycin B concentrations (0-3 μM) over 7 months, herein 231-JB cells. The 231-JB cells were cross-resistant to jadomycin F and S but not to the comparator drugs mitoxantrone, doxorubicin, and SN-38. The 231-JB cells did not have increased mRNA expression of topoisomerase-2 nor ABCB1 and ABCG2. Cyclooxygenase-2 (COX-2) increased by 25-fold, but expression of prostaglandin E₂ receptor 4 did not significantly change. Cotreatment with celecoxib (15-45 μM), a COX-2 inhibitor, resensitized the 231-JB cells to jadomycin B (IC₅₀ = 1.41 ± 0.24 to 0.75 ± 0.31 μM vs 2.28 ± 0.54 with 0 μM celecoxib). To our knowledge, this work represents the first report of the involvement of COX-2 in jadomycin B activity in vitro, proving to be an exciting new target for the exploration of jadomycin B anticancer activity. SIGNIFICANCE STATEMENT: Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin production, is associated with procancer signaling. COX-2, ABCB1, and ABCG2 overexpression are typically correlated in cancer, contributing to chemotherapy resistance. We observed increased COX-2, but not ABCG2 or ABCB1, expression in 231-JB cells. This indicates that jadomycin B triggers a distinct resistance mechanism. The COX-2 inhibitor celecoxib reversed jadomycin B resistance in 231-JB cells. As such, 231-JB cells represent an important model for COX-2 signaling in breast cancer and jadomycin B mechanism of action.

项与 IWK Health Centre 相关的新闻（医药）

2024-10-24

·GlobeNewswire-Health Care

Women’s Health Collective Canada Welcomes the IWK Foundation as Its Newest Member, Expanding National Alliance for the Advancement of Women’s Health Research

TORONTO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC), a strategic alliance of leading women’s health and hospital foundations from across Canada, is proud to announce the addition of the IWK Foundation to its membership. The IWK Foundation, located in Halifax, Nova Scotia, raises funds to support IWK Health which is renowned for its comprehensive research and healthcare services for women and children across the Maritimes and beyond. Its entry into the Collective marks a significant milestone for WHCC as the first new member to join since the alliance was founded in 2021. The expansion solidifies WHCC’s position as one of Canada’s foremost women’s health charities, establishing it as a truly coast-to-coast alliance. This growth strengthens WHCC’s ability to engage a nationwide audience and corporate partners, broadening its reach and enhancing its capacity to address critical women's health issues through impactful fundraising. “We are excited to welcome the IWK Foundation to WHCC,” said Sharlene Rutherford, President and CEO, Alberta Women’s Health Foundation, a founding member of WHCC. “This not only strengthens our position to improve women's health across Canada, but also sends a powerful message that women’s health and research is an issue we need to take seriously and work collaboratively to address. Together, we will continue to move the needle and make a tangible impact on the lives of women in Canada.” “The IWK Foundation is proud to join the Women’s Health Collective Canada,” said Jennifer Gillivan, President and CEO, IWK Foundation. “This alliance enhances our ability to address the pressing health needs of women by driving research that will improve care for generations to come. We are honored to join a group of outstanding organizations with a shared commitment to women’s health, and to be part of creating a better, healthier future for all women.” About Women’s Health Collective Canada Women’s Health Collective Canada (WHCC) is a strategic alliance founded by three of Canada’s leading women’s health and hospital foundations to support funding and equity in women’s health research, with unified action across Canada. Through intentional collaboration, WHCC foundations are bringing resources and fundraising together to address the legacy of inequity in women's health research. WHCC consists of the BC Women's Health Foundation, Alberta Women’s Health Foundation, Women’s College Hospital Foundation and the IWK Foundation. To learn more about WHCC, our members and their work, or to donate, please visit www.whcc.ca. About the IWK Foundation The IWK Foundation is a champion of excellence in women's and children's health and medicine and works in partnership with IWK Health to support their vision of providing quality care to women, children, youth and families in the Maritime Provinces and beyond. Our donors are passionately committed to making a difference for Maritime families, contributing over $25.2 million in support of the most urgent care priorities at the IWK last year. Funds raised also support the IWK's global leadership in research and knowledge sharing, which in turn improves lives worldwide. Visit www.iwkfoundation.org for more information. For media inquiries, please contact: Daniel St. Germaine | A&C | daniel@acteam.ca

2024-05-09

·药融圈

德国IWK—制药、医疗技术和化妆品行业领先的全球包装系统供应商 | 汇聚北京CPI2024

2024.5.10-11 • 中国北京CPI•2024 中国制药工业博览会展位号：A02号*转发文章到朋友圈赠送会议当天午餐券（简餐），数量有限，提前登记，现场先到先得！IWK原创软管灌装系统只需按一下按钮即可实现性能。IWK软管灌装系统可靠、快速、安全，且具有高可用性。GMP标准保证卫生生产。IWK软管灌装系统干净、安全、快速、准确基于最佳工艺顺序和高工艺安全性的最高性能和可靠性使IWK成为自动软管灌装机的市场领导者。与具有100%重量控制和一致闭合质量的第三方系统相比，IWK系统的灌装速度快20%。根据您的包装线布局，我们的IWK软管灌装机每分钟可处理40至760个卡套管。稳定的链式输送机和协调的机械装置可最大限度地减少维护并确保高可用性。过程自动化中减少和简化的设置操作提供了高度的灵活性和可靠性。由于模块化的概念，可以随时对各种特殊应用进行技术升级。IWK软管灌装机的卫生生产制药工业尤其对液体或半固体产品的卫生填充提出了很高的要求。IWK软管灌装机是根据GMP标准设计的。内置的Lobe泵和与产品接触的零件的光滑不锈钢表面可以快速安全地清洁。由于驱动机构与灌装区域的一致分离，灌装产品不会受到污染。无菌灌装过程是可实现的。制药公司值得信赖的合作伙伴由于其灵活性和适应性，IWK的软管灌装系统可以轻松处理不同类型的药物软膏和凝胶，无论粘度、稠度或成分如何。这使它们成为制药公司寻找可靠高效的产品填充解决方案的理想选择。凭借对质量、创新和客户满意度的高度关注，IWK继续在药用软膏和凝胶填充行业树立标准。凭借多年的经验和对卓越的承诺，他们仍然是寻求世界级解决方案以满足其灌装需求的公司值得信赖的合作伙伴。关于IWKIWK Verpackungstechnik GmbH是制药、医疗技术和化妆品行业领先的全球包装系统供应商，自1893年以来一直代表着具有卓越性能和最大可靠性的尖端技术。服务范围包括复杂生产线和单个部件的开发、设计、制造、组装和调试。一次、二次和三次包装的灌装和包装专家为客户提供建议和支持。IWK是ATS公司的一部分，以最高水平的创新技术和全面的服务在全球范围内运营。www.iwk.de点击图片查看大会具体议程↓↓关于药融圈药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等领域，品牌会议包括中国国际生物及化学制药产业大会，药物递送系列峰会，新药创新者系列峰会，服务了百余家上市/独角兽/生物技术/制药企业。

2024-01-23

·PRNewswire

Nova Scotia to Improve Revenue Management Processes with Infor

New "One Person One Record" program prioritizes the modernization of information systems with Infor Healthcare Revenue Cycle Management application NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Infor®, the industry cloud company, today announced that Nova Scotia Health and IWK Health have selected the Infor Healthcare Revenue Cycle Management application to help meet the goals of its digital transformation program, One Person One Record (OPOR). This major program will replace health information systems used throughout the province of Nova Scotia with a new clinical information system. As part of the transformation, key Infor applications will be used to modernize and unify disparate patient accounting and billing systems. "During our selection process, Infor demonstrated its understanding of the vision and strategic direction of One Person One Record, and how billing systems are part of the overall transformation," said Scott McKenna, chief information officer, Nova Scotia Health and IWK Health. "This technology will consolidate and streamline client and patient billing, payments, and follow-up for cases such as out-of-country patients or uninsured patients." Nova Scotia Health is the largest provider of health services in Nova Scotia. Its workforce of over 24,000 provides healthcare and support services in hospitals, health centers, and community-based programs across the province. IWK Health provides collaborative high-quality care to women, children, youth, and families in the Maritime provinces and beyond. Services are delivered through our Children's Health program, Mental Health and Addictions program, and Women's and Newborn Health. IWK Health's approach integrates talented people with new technologies, research, training, and clinical excellence to provide complex levels of care across our region. Nova Scotia is currently undergoing a multitude of groundbreaking digital health transformation projects aimed at revolutionizing healthcare delivery and improving the well-being of its citizens. These initiatives span a diverse range of areas, including electronic medical records implementation. "Modern healthcare organizations understand that their success depends on more than balancing the books every month. It is paramount that they focus on driving efficiencies through improved workflows and communications," said Travis Hatmaker, Infor senior vice president, industry and solution strategy. "Accurate and available patient accounts and related billing processes can make an enormous difference in improving overall efficiency. Infor is a trusted partner in the industry because we work with our customers to deeply understand the nuances of healthcare, beyond technology - we understand the difference between patient care and caring for the business, and we have a unique perspective on how to bring those two things together to solve the challenges that organizations are facing today." Learn more about Infor Healthcare: . About Infor Infor is a global leader in business cloud software specialized by industry. We develop complete solutions for our focus industries. Infor's mission-critical enterprise applications and services are designed to deliver sustainable operational advantages with security and faster time to value. Over 60,000 organizations in more than 175 countries rely on Infor's 17,000 employees to help achieve their business goals. As a Koch company, our financial strength, ownership structure, and long-term view empower us to foster enduring, mutually beneficial relationships with our customers. Visit . Media contact: Alexandria Truby Infor [email protected] 313-246-4268 Copyright ©2023 Infor. All rights reserved. The word and design marks set forth herein are trademarks and/or registered trademarks of Infor and/or related affiliates and subsidiaries. All other trademarks listed herein are the property of their respective owners. . SOURCE Infor

100 项与 IWK Health Centre 相关的药物交易

登录后查看更多信息

100 项与 IWK Health Centre 相关的转化医学

登录后查看更多信息